RealPharma: Conversations with Pharma Pathfinders

RealPharma

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare. RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.

  1. Formulation as Strategy: Why CDMOs Matter More Than Ever

    DEC 15

    Formulation as Strategy: Why CDMOs Matter More Than Ever

    Episode Title: Formulation as Strategy: Why CDMOs Matter More Than Ever Guest: Elizabeth Hickman, President & CEO, Austin Pharmaceutics Episode Overview In this episode of RealPharma, hosts Nari Oh and Ian Wendt sit down with Elizabeth Hickman, President and CEO of Austin Pharmaceutics, to unpack one of the most critical—and often misunderstood—elements of drug development: formulation and the evolving role of CDMOs. As drug molecules become more complex and solubility challenges grow, CDMOs are no longer just manufacturing vendors. They are strategic partners helping biotech and pharma companies bridge the gap between discovery and commercialization. Elizabeth shares her journey from commercial pharma leadership to running a science-driven CDMO, and explains why formulation decisions made early can determine whether a promising molecule ever reaches patients. 🔍 Key Topics Covered The expanding role of CDMOs Why CDMOs are shifting from executional partners to strategic extensions of pharma and biotech teams. Why formulation is make-or-break How solubility and bioavailability challenges derail up to 80% of modern drug candidates—and why these issues must be addressed early. From “undruggable” to developable How AI-driven discovery and structure-based drug design are unlocking new targets while creating new development hurdles. Inside Austin Pharmaceuticals’ approach A look at Austin’s proprietary Kinetisol® technology and how amorphous solid dispersion can improve bioavailability, scalability, manufacturability, and sustainability. Small biotech vs. big pharma dynamics What early-stage companies should look for in a CDMO partner—and the most common mistakes teams make when selecting one. Patient impact starts with formulation How pill burden, dosing frequency, and manufacturability directly affect adherence, cost, and competitiveness. The future of CDMOs Reshoring, cost pressures, AI adoption, and the growing need for talent with both scientific depth and entrepreneurial mindset. 💡 Memorable Takeaways “Formulation is where promising molecules either become viable drugs—or stall out.” Solving in-vivo performance alone isn’t enough; scalability and manufacturability must be designed in from day one. The best CDMO relationships are built on transparency, urgency, and shared long-term vision. Advanced formulation isn’t just a technical advantage—it’s a competitive and economic one. 👤 About the Guest Elizabeth Hickman is President and CEO of Austin Pharmaceutics, a U.S.-based early-phase CDMO specializing in formulation development for challenging small-molecule drugs. With a background spanning commercial strategy, drug launches, and executive leadership, Elizabeth brings a sponsor-centric mindset to CDMO partnerships—helping clients accelerate innovation while reducing risk.

    46 min
  2. Untangling the IRA with Emma Cousin

    DEC 8

    Untangling the IRA with Emma Cousin

    🎧 Hosts: Na-Ri Oh & Ian Wendt 🎓 Special Guests: Emma Cousin (PhD Candidate, Choice Institute – UW), Amos Fung (RealPharma Intern & Student Pharmacist) 🔍 Episode Summary: In this thought-provoking episode, hosts Na-Ri Oh and Ian Wendt sit down with Emma Cousin, a PhD candidate at the Choice Institute, University of Washington, to unpack the real-world implications of the Inflation Reduction Act (IRA)—particularly the Medicare Drug Price Negotiation Program. Joining them is Amos Fung, a RealPharma intern who brings a front-line pharmacy perspective to the policy conversation. Together, they discuss: 📜 A primer on the IRA’s healthcare provisions—what it is, how it came to be, and why it matters now. 💊 How CMS selects drugs for Medicare negotiation and whether this process constitutes true “negotiation.” 👩‍⚕️ The ripple effects on pharmacists, pharmacies, and patient care. 💸 The looming concerns around cashflow, operational readiness, and access as the 2026 implementation date approaches. 🧠 How researchers like Emma are modeling long-term effects—and what metrics we’ll need to track to assess the IRA’s success. 🔄 Unintended consequences and who might be left behind—especially independent pharmacies and vulnerable communities. 📈 A candid discussion on myths around drug pricing and why “good intentions” in policy still need strong evidence and thoughtful execution. 🎯 Key Takeaways: The IRA marks the first time Medicare can directly negotiate drug prices—albeit in a tightly structured format that raises questions about the fairness of “negotiation.” Pharmacies face operational and financial strain, particularly smaller or independent ones, due to rebate lags and implementation complexities. Patients will benefit from caps on out-of-pocket costs, but awareness and education are lacking—many don’t realize what the law offers. Stakeholders like pharmacists, researchers, and policy influencers need better communication and clearer technical standards from CMS. Evidence-based policy should be the north star for drug pricing reforms, but real-world implementation remains messy and evolving. 🧠 Resources & Mentions: Brian Reid & Adam Fein – Top newsletters to follow for updates on drug pricing policy. CMS Guidance Documents – Frequently updated, but often inaccessible to non-policy experts. National Pharmaceutical Council, Milliman, Portal (Harvard) – Organizations doing forward-looking modeling and policy impact research.

    47 min
  3. Reinventing Cell Therapy with Acoustics

    NOV 24

    Reinventing Cell Therapy with Acoustics

    Reinventing Cell Therapy with Acoustics, Microfluidics & High-Throughput Engineering In this episode, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Andrew Gray — immune cell engineer, biotech founder, venture capitalist, and CEO of CellEcho — to explore how a new acoustic-powered gene-delivery platform may redefine the boundaries of cell therapy. The conversation spans the current state of the cell therapy landscape, the persistent barriers to scalability, and why CellEcho’s ASOP platform (Acoustically Stabilized Oscillatory Pockets) could unlock a new era of faster, cheaper, and more effective cell engineering. 🔬 Episode Highlights 1. The State of Cell Therapy: Breakthroughs & Bottlenecks Despite scientific success, many pharma companies are exiting cell therapy due to cost, complexity, and manufacturing burdens. Conversely, major players like BMS continue doubling down, acquiring companies such as Orbital Therapeutics. Autologous therapies remain logistically overwhelming and expensive—often ~$400k per dose. 2. Why Cell Therapy Is So Hard to Scale “Vein-to-vein” timelines are still measured in weeks, not days. Manufacturing is bespoke: each patient’s cells must be extracted, engineered, expanded, frozen, shipped, and reinfused. Viral vectors and current non-viral delivery methods introduce cost, complexity, and biological limits. 3. The Next Frontier: In Vivo, Allogeneic & Beyond Allogeneic CAR-Ts remain challenging due to immune rejection and complex engineering. In vivo CAR-T offers promise but is limited by the small genetic “payload capacity” of lipid nanoparticles. Solid tumors remain particularly difficult: only ~9% response rates in some indications. 4. Introducing CellEcho & the ASOP Platform CellEcho’s technology emerged from UC Irvine’s microfluidics program. By applying precision acoustic energy, the platform can: Hold cells in place using thousands of stable micro-eddies Open controlled, programmable “portals” in cell membranes Sequentially deliver multiple genetic payloads with high efficiency Achieve 1 billion cells/hour processing rates Reduce dose production costs by ~100× Enable high-throughput engineering, not just manufacturing This unlocks the ability to test dozens to hundreds of engineered CAR-T variants in days—rather than the years needed today. One academic lab spent 6 years evaluating 11 CAR-T variants. CellEcho tested 8 variants in under 48 hours — and aims for 100+ per week. 5. From Better Manufacturing to Better Medicines While CellEcho originally targeted faster manufacturing, Andrew shares that the bigger opportunity is designing entirely better therapies, not simply making today’s ones faster. This includes: Engineering CAR-Ts with multiple CAR constructs Arming cells with resistance to tumor suppression signals Precise control over expression levels (avoiding under- or over-expression) Unlocking new indications: autoimmunity, neurodegeneration, regenerative medicine 6. Personal Motivation & Mission Andrew shares how his mother's struggle with myasthenia gravis sparked his lifelong journey in immunology. His 20-year career investigating immune evasion, Tregs, and tumor microenvironments culminated in his conviction that next-generation cell engineering is essential. 7. What’s Next for CellEcho Currently initiating pre-seed fundraising Supported by multiple federal grants (including NSF SBIR) Expanding early partnerships with Stanford, Mass General Brigham, and industry collaborators Building a fully automated, AI-augmented cell therapy design platform Dual strategy: Cell-therapy-development-as-a-service Proprietary therapeutic pipeline in select indications 💡 Key Takeaways Cell therapy works — but not broadly or efficiently enough. Engineering complexity, not biology alone, is the rate-limiting step. Acoustic microfluidics enables a scalable, programmable, non-viral way to engineer living cells. High-throughput screening for cell therapies could transform discovery the way combinatorial chemistry transformed small molecules. The real revolution isn’t just faster production — it’s better, more sophisticated therapies. 🔗 Learn More About CellEcho Visit: https://cellechobio.com Contact: Via the Info link on the website (messages route directly to Dr. Gray).

    52 min
  4. NOV 10

    Food as Medicine: Promise, Pitfalls, and the Politics of the Plate

    👩‍🔬👨‍⚕️ Hosts: Na-Ri Oh & Ian Wendt 🎧 Guest: Dr. Ron Shigeta – Biotech visionary, co-founder of IndieBio, and food innovation expert. 🧬 Episode Summary: In this deeply insightful and refreshingly candid episode, Ian and Nari welcome back biotech veteran Dr. Ron Shigeta to explore the evolving landscape where food, health, and biotech collide. From the collapse of the lab-grown meat hype cycle to the challenges of democratizing access to functional food, Ron brings hard truths, historical context, and cautious optimism to the table. As the U.S. federal government embraces its Make America Healthy Again (MAHA) agenda—reforming food policy to prioritize public health—the conversation asks: 👉 Can we finally treat food as medicine, and make it scalable, credible, and affordable? 👉 What went wrong with cultured meat—and what comes next? 👉 Why does Ron really hate the term “food tech”? If you’ve ever wondered whether the future of wellness lies in your fridge, your pharmacy, or your feed, this one’s for you. 🔑 Key Topics Covered: MAHA & Food Policy Shifts: What the government’s new approach to food says about public health—and why it matters. Cultured Meat's Cautionary Tale: Why the dream of lab-grown meat stumbled—and how the next wave of companies might succeed. Ultra-Processed vs. Ultra-Useful: A frank conversation on consumer trust, marketing blunders, and what “processed” really means. Food as Preventative Medicine: From diabetes to GLP-1s to micronutrients—why we’re ignoring the obvious. Pharma’s Cost Spiral & Innovation Trap: $2M gene therapies, $500K cancer cures, and why food might be the only scalable solution left. The Neuroscience of Eating: Food isn’t just fuel—it’s identity, emotion, and the deepest form of human behavior. Why “Food Tech” is Bad Branding: Ron’s passionate take on why the tech world misunderstands how people eat. 🧠 Memorable Quotes: “Technology for the public will always win—because once people use it, they can’t let it go.” – Ron Shigeta “We’ve invented healthcare Americans can’t afford.” – Ron Shigeta “Nobody buys food because it’s high-tech. Nobody. That’s not how trust is built.” – Ron Shigeta 📚 Mentioned in This Episode: MAHA (Make America Healthy Again) policy initiative GLP-1s and the rise of preventative obesity drugs Blue zones and the elusive science of longevity Golden rice and biotech’s public trust problem OneSkin and peptide-based functional cosmetics Ron’s upcoming book on food, neuroscience, and the future of health

    54 min
  5. Where Policy Meets the Pharmacy Counter

    OCT 13

    Where Policy Meets the Pharmacy Counter

    Where Policy Meets the Pharmacy Counter Featuring Congressman Jake Auchincloss Episode Summary In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Congressman Jake Auchincloss (MA-04) to dissect the tangled web of policy, profit, and politics driving America’s drug pricing system. From pharmacy benefit managers (PBMs) to the politics of tariffs, this discussion explores the push for transparency, fair competition, and sustainable reform in healthcare. Auchincloss, a Marine veteran and member of the House Energy and Commerce Committee, brings a rare combination of policy depth and industry fluency. Together, they unpack how entrenched middlemen have distorted the system—and what bipartisan solutions could finally restore balance between innovation and access. What You’ll Learn: Why PBM reform has momentum but keeps stalling in Congress How the Pharmacists Fight Back Act could level the playing field for independent pharmacies The purpose of the Patients Before Monopolies Act and how it targets vertical integration Auchincloss’s vision for a “biotech social contract” that links innovation, IP protection, and insurance design The real story behind drug import tariffs and the risks of chaotic trade policy How U.S. innovation compares to China’s rapidly advancing biotech ecosystem The importance of aligning drug pricing reform with patient access and national competitiveness Memorable Moments: “PBMs deserve to be bulldozed for their behavior over the last two decades.” “There’s no moral hazard in getting sick—no one fakes chemotherapy to get free drugs.” “The most expensive thing in the world is what hasn’t been invented yet.” Why It Matters: As drug costs rise and innovation races ahead, the U.S. faces a defining choice: will healthcare policy reward breakthroughs or bureaucracy? Congressman Auchincloss argues that reform is not just about prices—it’s about preserving America’s leadership in biomedical innovation while ensuring patients can actually access the medicines that save lives. Guest: Congressman Jake Auchincloss U.S. Representative for Massachusetts’ 4th District Member, House Committee on Energy and Commerce Hosts: Na-Ri Oh & Ian Wendt

    55 min
  6. Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare

    OCT 6

    Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare

    Episode Title: “Conversations, Not Campaigns: The Art of Authentic Engagement in Healthcare” 🗣️ Episode Summary In this episode, hosts Dr. Na-Ri Oh and Ian Wendt sit down with Colin Hung — healthcare technologist, marketing strategist, and co-founder of the long-running #HCLDR (Healthcare Leadership) Twitter community. Colin shares his journey from biomedical engineering to becoming one of the most respected community builders in digital health. Together, they explore what authentic engagement really looks like in the healthcare and pharma industries — from how companies can move beyond broadcasting to truly listening, to how AI can support rather than replace human connection in patient advocacy. 🧭 Key Themes & Takeaways From Engineer to Connector: How Colin’s early career in biomedical engineering shaped his systems-thinking approach to digital health. Building #HCLDR: The story behind one of the most influential online healthcare communities — what made it work, and how it evolved over 13 years. Conversation > Communication: Why genuine listening and empathy are more powerful than any marketing message in healthcare engagement. Pharma’s Challenge: How manufacturers can engage meaningfully online despite regulatory constraints — and why showing up as people first matters most. AI in Healthcare: The promise and pitfalls of AI in patient engagement — and how to use it responsibly to empower, not replace, the human touch. The Future of Digital Communities: What comes next for online healthcare engagement now that #HCLDR has passed the torch to new community creators. 👥 Guest Bio: Colin Hung Colin Hung is a healthcare technologist, community strategist, and co-founder of the #HCLDR community. With more than 25 years in health IT, Colin has been a driving force in bringing together patients, clinicians, and innovators to discuss the future of care. He’s also a writer, speaker, and advocate for inclusive, patient-centered technology. 🔗 Connect with Colin: LinkedIn: https://www.linkedin.com/in/colinhung/ Twitter (X): https://twitter.com/Colin_Hung 🏷️ Organizations, Movements & Mentions #HCLDR (Healthcare Leadership) — A global online healthcare leadership community founded in 2012 that brought together patients, providers, and industry leaders for weekly discussions on improving healthcare. 🔗 https://hcldr.wordpress.com 🔗 https://twitter.com/search?q=%23HCLDR       🎧 Listen & Subscribe Find The RealPharma Podcast on: Spotify Apple Podcasts Google Podcasts

    53 min
  7. Building the Highway for AI in Pharma: A Conversation with Ilya Burkov

    SEP 22

    Building the Highway for AI in Pharma: A Conversation with Ilya Burkov

    🎙️ Episode Title: Building the Highway for AI in Pharma: A Conversation with Ilya Burkov 📍 Episode Summary In this episode of RealPharma, hosts Na-Ri Oh and Ian Wendt sit down with Dr. Ilya Burkov, Head of AI Cloud at Nebius, to explore the critical infrastructure enabling the AI revolution in drug development. While the headlines often focus on the promise of AI, Ilya brings us backstage—where the real acceleration happens. From GPU scalability and regulatory compliance to synthetic data and digital twins, this conversation unpacks how the roads, bridges, and power lines of cloud infrastructure are shaping the future of biopharma R&D. Whether you're a biotech founder, pharma executive, or AI enthusiast, this episode offers a 360° view into the unseen tech powering the next generation of therapies. 🧠 What You’ll Learn Why AI needs more than just models—it needs muscle. The role of GPUs-as-a-service in reducing drug discovery timelines How infrastructure and compliance go hand in hand in regulated industries Why digital twins and synthetic control arms could be the future of clinical trials Challenges biotech startups face—and how AI-first models could level the playing field The ethical promise of fully virtual drug pipelines     🧭 Key Quote “Think of AI in pharma as the car. What we’re building is the highway—bridges, power, road signs—so researchers can just drive.” — Dr. Ilya Burkov   🧰 Resources & Mentions Ilya Burkov on LinkedIn Nebius AI Cloud FDA Digital Health Initiatives 👥 About the Guest Dr. Ilya Burkov is Head of AI Cloud at Nebius, where he leads teams building cloud platforms purpose-built for AI workloads in life sciences. With a background in large-scale computing and a deep understanding of compliance in regulated industries, Ilya bridges the gap between bleeding-edge technology and real-world healthcare impact. 🎧 Listen & Subscribe Find RealPharma on your favorite podcast platform: Apple Podcasts | Spotify | Amazon Music  👉 Don’t forget to rate and review the show—it helps others discover the future of pharma!

    48 min
5
out of 5
12 Ratings

About

For biopharma pros seeking insightful discussions and a deeper understanding of the pharma world, join Dr. Na-Ri Oh and Ian Wendt as they talk with industry leaders and luminaries to delve into biotechnology, pharmaceuticals, and healthcare. RealPharma podcast aims to challenge your viewpoints, deepen your understanding of the pharma world beyond the headlines, and explore emerging trends in medical innovation.

You Might Also Like